"Hope, like the gleaming taper’s light, Adorns and cheers our way;
And still, as darker grows the night, Emits a brighter ray."
— Oliver Goldsmith (1730?–1774)

CML Medical Journal Articles

  • Home
  • Gleevec Resource Center
  • Back to CML Medical Journal Articles


      Journal Articles About CML

    BLOOD

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
    Blood, April 15, 2004

  • BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells
    Blood, April 15, 2004

  • A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
    Blood, Feb. 1, 2004

  • Inhibitory effect of imatinib on normal progenitor cells in vitro
    Blood, Jan. 15, 2004

  • Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
    Blood, Jan. 15, 2004

  • Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
    Blood, Jan. 15, 2004

  • Imatinib mesylate affects the development and function of dendritic cells generated from CD34-positive peripheral blood progenitor cells
    Blood, Jan. 15, 2004

  • Imatinib and plasmacytoid dendritic cell function in chronic myeloid leukemia patients
    Blood, Jan. 8, 2004

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia-chromosome positive chronic myeloid leukemia
    Blood, Dec. 24, 2003

  • Molecular response to imatinib in late chronic phase chronic myeloid leukemia
    Blood, Nov. 26, 2003

  • To the editor: Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib
    Blood, Aug. 1, 2003, Vol. 102, No. 3

  • Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-a
    Blood, July 1, 2003, Vol. 102, No. 1

  • Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase
    Blood, June 1, 2003, Vol. 101, No. 11

  • Prognostic significance of cytogenetic clonal evolution in patients with chronic myeloid leukemia on imatinib mesylate therapy
    Blood, May 15, 2003 Vol. 101, No. 10

  • Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Blood, Sept. 1, 2002, Vol. 100, No. 5

  • The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML
    Blood, Sept. 1, 2002, Vol. 100, No. 5

  • Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
    Blood, Aug. 1, 2002, Vol. 100, No. 3

  • Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months’ experience
    Blood, July 15, 2002, Vol. 100, No. 2

  • Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
    Blood, July 15, 2002, Vol. 100, No. 2

  • "Imatinib Induces Hematologic And Cytogenetic Responses In Patients With Chronic Myelogenous Leukemia In Myeloid Blast Crisis: Results Of A Phase II Study"
    Blood, May 15, 2002, Vol. 99, No. 10

  • "Imatinib Mesylate (STI571) Therapy For Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia In Blast Phase"
    Blood, May 15, 2002, Vol. 99, No. 10

  • "CML Yields A Few More Clues"
    Blood, May 15, 2002, Vol. 99, No. 10

  • "Factors Affecting Duration Of Survival After Onset Of Blastic Transformation Of Chronic Myeloid Leukemia"
    Blood, April 1, 2002 Vol. 99, No. 7

  • "Imatinib Induces Durable Hematologic And Cytogenetic Responses In Patients With Accelerated Phase Chronic Myeloid Leukemia: Results Of A Phase 2 Study"
    Blood, March 15, 2002 Vol. 99, No. 6

  • "Allogeneic Bone Marrow Transplantation For Chronic Myelogenous Leukemia: Comparative Analysis Of Unrelated Versus Matched Sibling Donor Transplantation"
    Blood, March 15, 2002 Vol. 99, No. 6

  • "Leukemic Target Susceptibility To Natural Killer Cytotoxicity: Relationship With BCR-ABL Expression"
    Blood, March 15, 2002 Vol. 99, No. 6

  • "Prognostic Significance Of Cellular Vascular Endothelial Growth Factor Expression In Chronic Phase Chronic Myeloid Leukemia"
    Blood, March 15, 2002 Vol. 99, No. 6

  • "A Randomized Study Of Interferon-a Versus Interferon-a And Low-Dose Arabinosyl Cytosine In Chronic Myeloid Leukemia"
    Blood, March 1, 2002 Vol. 99, No. 5

  • "Sustained Response To Recombinant Human Erythropoietin And Intermittent All-Trans Retinoic Acid In Patients With Myelodysplastic Syndromes"
    Blood, March 1, 2002 Vol. 99, No. 5

  • "Brief Report: Ph+ Acute Lymphoblastic Leukemia Resistant To The Tyrosine Kinase Inhibitor STI571 Has A Unique BCR-ABL Gene Mutation"
    Blood, March 1, 2002 Vol. 99, No. 5

  • "Improved Disease-Free–Survival After Transplantation Of Peripheral Blood Stem Cells As Compared With Bone Marrow From HLA-Identical Unrelated Donors In Patients With First Chronic Phase Chronic Myeloid Leukemia"
    Blood, Feb. 15, 2002

  • "Effects Of The Bcr/Abl Kinase Inhibitors STI571 And Adaphostin (NSC 680410) On Chronic Myelogenous Leukemia Cells In Vitro"
    Blood, Jan. 15, 2002, Vol. 99, No. 2

  • "Treatment Of Chronic Myelogenous Leukemia With The Tyrosine Kinase Inhibitor STI571 Results In Marked Regression Of Bone Marrow Fibrosis"
    Blood, Jan. 1, 2002, Vol. 99, No. 1

  • Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A
    Blood, Dec. 15, 2001, Vol. 98, No. 13
  • "Finally, Able To Present ABL"
    Blood, Nov. 15, 2001, Vol. 98, No. 10

  • "Direct Evidence That Leukemic Cells Present HLA-Associated Immunogenic Peptides Derived From The BCR-ABL b3a2 Fusion Protein"
    Blood, Nov. 15, 2001, Vol. 98, No. 10

  • Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
    Blood, Nov. 1, 2001, Vol. 98, No. 9
  • "Perspective: Chronic Myeloid Leukemia: Current Treatment Options"
    Blood, Oct. 1, 2001, Vol. 98, No. 7

  • "CGP57148B (STI-571) Induces Differentiation And Apoptosis And Sensitizes Bcr-Abl-Positive Human Leukemia Cells To Apoptosis Due To Antileukemic Drugs."
    Blood, September 2000

  • "Selection And Characterization Of BCR-ABL Positive Cell Lines With Differential Sensitivity To The Tyrosine Kinase Inhibitor STI571: Diverse Mechanisms Of Resistance"
    Blood, Aug. 1, 2000

  • "Inhibition Of C-Kit Receptor Tyrosine Kinase Activity By STI 571, A Selective Tyrosine Kinase Inhibitor."
    Blood, August 2000

  • "Mechanism of resistance to the ABLtyrosine kinase inhibitor STI571 in BCR/ABL–transformed hematopoietic cell lines" (Adobe Acrobat required)
    Blood, June 1, 2000

  • "Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification" (Adobe Acrobat required)
    Blood, March 1, 2000

  • "CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits The Growth Of Cells Expressing BCR-ABL, TEL-ABL, And TEL-PDGFR Fusion Proteins."
    Blood, December 1997





    • Give me a holler





    Today Is:





    © 2000-2004 CMLSupport.com Inc. All rights reserved.

    These contents may not be reproduced in whole or in part in any medium without the express written permission of CMLSupport.com Inc. This site is best viewed with Internet Explorer.

    		•